BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists will be the most aggressive in adopting biosimilars compared with other specialties because of their lower clinical trial requirements. According to Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology, Decision Resources expects biosimilar versions of granulocyte colony-stimulating factor (G-CSF) and monoclonal antibody (MAb) therapies used in oncology to erode more than $7 billion in brand sales in 2019 alone across the U.S., EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan markets.
Primary research reveals U.S oncologists in particular will more rapidly adopt biosimilars compared to their European counterparts. Compared with French and German oncologists, U.S. oncologists will require fewer and shorter Phase III clinical trials before they feel comfortable prescribing biosimilars. The majority of surveyed U.S. oncologists would require one trial lasting 12 months or less for biosimilar G-CSFs and at most two clinical trials lasting two years or less for biosimilar MAbs before they feel comfortable prescribing biosimilars. Surveyed solid-tumor oncologists across countries have higher expectations for clinical trials of biosimilar MAbs than for biosimilar G-CSFs.
Across the U.S., France and Germany, the majority of surveyed oncologists expect to begin prescribing biosimilars within 12 months after launch, contributing to the rapid erosion of branded G-CSFs and MAbs.
"Because of patent expiries and more established regulatory pathways for approving biosimilars in Europe, most biosimilar MAbs will launch in the EU5 before the United States," said Decision Resources Analyst Cindy Fung, Ph.D. "As a result, U.S. physicians will likely benefit from clinical experience in European markets that will increase their rate of adopting these agents."
The Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German solid-tumor oncologists and hematologist-oncologists to highlight the key expectations that will drive or constrain biosimilar adoption.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
SOURCE Decision Resources